加州再生医学研究所资助的干细胞治疗临床试验

botizhou

Funding Clinical Trials8 g8 f: N$ }' `0 i  S0 f# m; ?2 L
Before a new therapy is widely available in doctors' offices, it goes through several rounds of carefully regulated testing in people. These happen in three stages:6 S  W7 T+ v/ u2 E7 t+ y
1.        Phase 1 trials include a very small number of people and are primarily intended to test whether the proposed therapy is safe.
# i- k. L' Y% B$ Q2.        Phase 2 trials include slightly more people and are intended to verify that the therapy is safe, and to start looking into whether it is effective at treating the disease or condition.+ x9 E) m" |8 ]0 P2 j" O9 i% [
3.        Phase 3 trials include large numbers of people and are intended to test whether the therapy treats the disease or condition.
% A3 o* j2 D3 hThe vast majority of clinical trials carried out in the United States are required to be listed on the clinicaltrials.gov website. Those trials being carried out in other countries won't always have additional trial details available through that site.
1 ]; w7 }$ [# H+ v0 R8 F, a2 ?CIRM-Funded Clinical Trials
2 K2 _% G( v% S! a. d7 y5 X% IThese clinical trials have been funded by grants from CIRM.
$ E6 [9 r, T( z5 N$ i+ mGrantee        Disease        Grant        Trial details
1 w/ u2 O% t7 K8 D; eclick on the NCT link for more info
2 c5 v: k' j, nAsterias Biotherapeutics
3 e! ?4 X5 n% c$ @1 w; e# w9 qSpinal Cord Injury
/ u  M" V- o1 c( FStrategic Partnership III Track A
4 F. C  s: f6 f$ C' ?6 YPhase 1/2a
7 z4 G6 J* j8 U( kNCT023021575 r; p) K/ }+ q) ~2 G% ^
- L8 b1 T! R) x/ B0 g
Calimmune
) l, A( W: e7 |& F( ^$ a. rHIV/AIDS
& l, z2 N7 Y! O, s7 g% VDisease Team
2 M% {6 Y( g% z2 x  E% M- zPhase 1/21 N& K# f8 q  ^; i- D$ J( n
NCT01734850% l  t# R+ B% f" E3 i' L
+ }( p! k9 V% |
Capricor
7 q/ U, A( n" D; T1 K6 u% lCardiomyopathy Secondary to Duchenne Muscular Dystrophy8 J- D8 H1 I9 B# u
Clinical Trial Stage Projects
. i0 M0 b! w9 r& d" v8 sPhase 1/2
& a  f3 L% a% H; L6 m0 @NCT02485938
# x$ e+ r5 M8 k* D1 G# o0 [+ y1 w& e* D+ j7 p. q% ^7 b1 u& b+ U
Capricor& a! g4 D2 N% z7 {
Heart disease
1 }7 }' r+ |% S+ eDisease Team4 R8 e+ i8 ]3 F  l! v
Phase 2
8 U+ {! u) Q3 C2 ANCT01458405% g3 u1 v$ E9 g& k8 s

+ n" T1 |/ N, {+ jCedars-Sinai Medical Center1 `" v" z/ [+ X1 O' m, e
Amyotrophic Lateral Sclerosis (ALS)
$ }% z8 V8 A5 L! KDisease Team Therapy Development
& Z0 q! M6 G# p* i+ ^: QPhase 1, `/ I; I: G' `8 _
NCT02943850! G; X0 R8 R  {4 G# o
. c+ W6 S# o3 h, f7 Y
Cedars-Sinai Medical Center- l( p6 T* `) X1 W7 ~% c2 c
Pulmonary hypertension        Clinical Trial Stage Projects
+ D, i2 O8 a! ZPhase 1a/2b+ J, `( l, i7 c7 ?
City of Hope, h5 K3 S4 p5 ^& `( p
Sangamo BioSciences
, B. @* g4 A& d9 n6 |: g+ DHIV/AIDS
! S6 z+ \0 c9 F! G5 lDisease Team4 I! _9 n7 s8 ]; n7 E# L4 N
Phase 1
# f7 r, c: w/ z$ r4 ?NCT02500849% o5 v6 j0 @* |% @+ q8 }

1 Q' X# K# I/ {& I/ ZForty Seven, Inc." Z/ E7 }& y: K. P
Solid tumors
4 ^& e, O0 ]4 m* `- u* f) G' hClinical Trial Stage Projects* q! |% t' _  ^  j7 a' b8 w
Phase 1b/26 N% ^* ?: w0 ~* t; Y' {5 _
NCT02953782- L$ ?/ B8 Z+ Z" l4 j8 u- H) Y

8 {) X; q0 ^7 s5 B( c$ L" I1 JHumacyte
  j  W& t1 x9 O! v" l' |Kidney disease        Clinical Trial Stage Projects
4 a( _2 o+ G: f; rPhase 3. s" G2 x2 m: H& @
NCT02644941
9 Y% Q) e$ O# {; B6 ?; Y% z; R/ o' H5 F! W3 Q/ \
ImmunoCellular6 C& |7 Z7 }4 |% k% i7 H
Glioblastoma (brain tumors)0 x; m* d( A, r7 M4 y& a0 ^
Clinical trial stage projects) T* e# p- T- f& F
Phase 3
7 P% E% |1 R+ \$ V" RNCT02546102
* J4 ]* Y. |$ p9 n9 D
$ s. k' U' D" q1 i; ^' z! o$ B' jjCyte, Inc.
1 O: n1 d6 d% b% S/ \8 TRetinitis Pigmentosa
! k2 M# F0 p% L  W5 z# X$ WClinical trial stage projects
6 Z2 I: `/ c- |& zPhase 2b( P2 p- Y# g0 \0 Y
Stanford
' S! h. \1 E( C! |Kidney Failure        Clinical trial stage projects
3 ?6 z. P$ G5 p. `Phase 1" \5 r8 g- }5 s
NCT00319657; [4 E6 C) E  w  P! {# U1 J5 Q/ y
+ c1 l. U" R9 S' \; I" a0 ]) U2 v
Stanford" A0 B# Q# x7 U* E7 B0 H; O& n8 ~
X-linked severe combined immunodeficiency syndrome (SCID)2 G- b; b1 Y* K9 `  \! S: n) d$ t" V
Disease Team Therapy Development# |- t1 a& }* z: A! y  I
Phase 1/2a
' `! n8 ^* ?6 \7 N: YNCT029630645 J" s6 H6 ]* Z( J( j$ }* X& B

6 s* I& C( m5 RUC Davis
# J% u9 n: G# C7 @HIV-related Lymphoma- k. a" M2 S0 p7 y1 F0 m2 \
Clinical trial stage projects% c( Q+ _- X0 K$ k
Phase 1/21 [6 Z$ g0 n$ s9 D) u
NCT02797470& R* n+ N9 l  B' O

0 e+ \, `1 n! FUC Davis8 G' u. [+ v4 M/ g
Huntington's disease
, i0 U0 V5 ~+ @" L. ~Disease Team3 ^# H' V: S8 p7 Q/ Q$ L
Observational9 ^, n- t: \- |# v3 K
NCT01937923" R  J$ ^# T& y) _

; I0 ]8 @% _1 C6 T: ^UC Davis# W; P, H# b$ W- f2 K2 O# S1 O# R1 w8 K6 K
Osteoporosis/ P  x9 Z$ [7 y& Y. @
Disease Team Therapy Development
; ]2 U5 a2 Z. H# U1 x9 B5 KPhase 1/2a
# g) y5 E8 d5 }8 M! A- @- zUC Irvine
- I1 I6 J; T9 r# A- r9 H  l$ vRetinitis Pigmentosa$ i  ^3 m5 E1 s. H6 Z
Disease Team Therapy Development
+ ^5 E& u) x1 A$ W1 b" v- f, BPhase 1/2
' M* Z7 G) Y, q; v8 P( ~" j4 nNCT02320812; r% Y6 t& m- y

- m% a. v4 m' m! D+ e; cUCLA
1 `' p# H0 k1 x4 E3 Y9 w7 sAdenosine Deaminase-Deficient Severe Combined Immunodeficiency (ADA-SCID)
* A$ ^- {, x* g( g( ~' u7 DClinical Trial Stage Projects1 J3 l1 u8 K3 G1 W2 L* D
Phase 2. ~% P3 E6 w2 H% \7 f" Y2 U
NCT01852071
+ v- L  \2 ]9 d9 h0 ^) p) B
9 E% R+ f4 }4 t) s1 `* WUCLA
3 f  @% Z/ \, D/ Z/ zChronic granulomatous disease' v7 o2 x3 }! k
Clinical Trial Stage Projects0 e2 }7 c/ f3 U- N, E' R* F
Phase 1
1 [# l2 W% N+ e9 o  q: aNCT02234934
! i7 |  @. X. U# G. `( s
0 {0 B+ e- P# E9 W  s" T; U3 _UCLA1 m- C; P$ n$ M. R0 [, B* `) ]
Sickle cell disease
* }) m; f  P$ B) FDisease Team
- b/ x9 Q$ g$ nPhase 1) j2 E; ?  Z) z6 S- l
NCT02247843
& K6 [0 w) [# q7 {' Z1 N; i1 ?6 J6 J! {" a# y2 h
UCLA: G: V5 P3 r$ q
Solid tumors3 F0 ]/ v) y& Y- [6 r
Disease Team
8 L' ]4 ^# F: E  IPhase 1
1 ?. V5 v$ ?! q7 u3 z/ CNCT019543161 [' F0 k. D2 @4 g2 G3 H& ]

& S2 Y1 I8 F: w1 D! W6 \USC; O, Q) J9 y* d1 o2 K* E2 l: V# l
Blindness" U: V( [9 C' H2 w, L6 @# o
Disease Team! I( G( j" A. z* v3 ]  J
Phase 1
  A6 ~: z8 D% gNCT02590692
. d; n4 p/ x; B) N, o0 B2 B' N
* }0 [" d  V9 j% }UCSD% T% F7 K8 F% T) a% a
Leukemia" C! l1 h6 e- }
Disease Team6 u. S: h" q, E# x! B- e
Phase 1
" B9 @1 f' _. P/ D, HNCT02222688. T/ {; k; V9 x: G
& [# o. ?. U/ p
Viacyte
/ u& G& G) A6 @& X" oDiabetes1 V/ o' K. V- {7 R0 {: u8 y# G
Strategic Partnership I
* i: Q# B7 f( V0 nPhase 1
' b# O0 ^+ W3 H) `7 QNCT022393543 G1 e4 D' Z, M% O' Y+ U9 ~' i

* K- e/ l. `. \  |3 sCaladrius Biosciences
5 h! G' A. u. o. c1 y5 E0 k" CSkin Cancer: Melanoma8 a7 ]7 F9 @% ~! `' F
Clinical Trial Stage Projects; M( t# _! z$ L- K$ O, h2 Q5 S
Phase 3
0 i+ T. Z) e& Y; t% ?" e' h7 PNCT01875653
* h2 _& L  a1 h# X, c2 YCLOSED
6 @. d1 ]; v9 HGeron1 e" Y, b7 i9 e( m; @. \
Spinal cord injury1 K! j8 q4 @; k; h" e
Targeted Clinical Development
0 @# h( f& x3 J* G6 ^1 lPhase 1# F7 m8 G! s* w7 h
NCT01217008
/ m: Y3 ]8 H  e0 l$ y7 f5 }% W( s6 d* wCLOSED0 @3 k) Q1 z( a' \: ?) C
Stanford
! `# D7 \2 p: M0 a) dSolid tumors5 A6 E1 _/ a* d1 Z
Disease Team  P9 {; y( d" H. e& j# ^4 y
Phase 1
. d) S0 U% c3 X. E' u1 ZNCT02678338% B+ |1 U7 v) n- G6 d
CLOSED; S) g4 k) C0 `+ C/ A$ O5 {
9 `" s0 Y& R7 ^5 i9 O
Clinical Trials Based on Earlier CIRM Grants
3 S/ A5 r( c0 f/ p; aThese clinical trials are based on discoveries made by our grantees when they were carrying out CIRM-funded research.
2 i/ P' ]5 V: B" Q' zGrantees        Trial sponsor        Disease        Supporting Grant        Trial details. i% h! n+ k  ?# H* g! B, P; Y- z) N; T
Mark Marsala6 j& |& \0 H$ f. W
Neuralstem
$ W4 t. O4 _8 xSpinal Cord Injury& Z* g6 T3 v! T; j' S
Comprehensive Grant/ D1 C& W9 g# J7 N- i1 W) g  T& x
Phase 1 NCT017728103 i5 h4 B4 P3 T

$ P9 |3 K6 E) i% A- zCatriona Jamieson! t1 P: n0 T' T8 q# E0 b
TargeGen/Sanofi        Myelofibrosis
+ x) ?1 H: K" b% cTraining
. d! J0 P7 G" J; @$ ?$ G& l" v' ^SEED
' w/ z( W1 v( u" qPhase 1' {: T+ b+ E) g& K) c3 H1 p7 u6 p9 V
NCT00631462- z: g% L% \- @2 D
Phase 1/26 z2 ~7 E8 l' z% @; x  _# P6 f
NCT007243345 u+ g: A9 k, k7 S/ W8 g* u

0 y1 A6 W8 M( o2 W$ R: ?2 ~Catriona Jamieson
9 H0 v& a. ~+ h* U9 ]Sanofi        Polycythemia vera6 d" }8 d. `" l0 q) {
Training
9 P/ q: D0 ?& ~1 v! aSEED
- U, t% _: z  [8 L) \9 e( w. xNew Faculty8 ~, P* m0 b4 t& s/ U
        Phase 2, R5 ^% v- P: G
NCT01420770
8 a' [% r4 n1 ^9 {. T% ]' k* x+ KPhase 2( L4 Q. z! k% H" z
NCT01420783
1 }* d% X- ?9 }Phase 2
. p+ L2 U* H& F7 oNCT015231719 U- T/ n$ g$ X! l' A0 g) @' A( M
Phase 3* Y3 W# N/ T4 v% P
NCT01437787
: x3 t' W9 ^' q) {CLOSED( A% a/ n- T( ~# ]! Y2 Z# R
Dennis Carson; s; D1 `, B8 K
Catriona Jamieson2 g/ C% E! u) M. s# t7 i+ I
John Dick        Pfizer        Leukemia
; n6 f* A( F9 o2 C5 |Disease Team
1 H1 g+ {! y0 P/ z5 ~/ gPhase 1, J7 s' U& \. S1 o2 d: i3 Q: G
NCT00953758& E5 o5 q  v; A( v3 k; C
Phase 1/23 x' v/ Y5 d  E0 s
NCT01546038
0 b2 f0 y! Y' F
3 D5 S8 Y3 A) |3 \$ e) c8 u6 |) x0 N& |! zJoel Gottesfeld' o( ?. o2 p+ w8 }! J; T! M
Repligen, Corp        Ataxia        Basic Biology
7 B$ G# J/ q" a+ w8 r+ mPhase 1 Italy/ B( [5 a/ ]4 u0 r
Antoni Ribas
* ~4 j8 A0 d/ O4 T" y6 |& wZoran Galic; i9 N+ K2 y1 S% f& M  z' O' ^# h
Jonsson Comprehensive Cancer Center        Metastatic melanoma0 Z/ n7 t2 T5 D
SEED
) H- H. I+ q# b. R8 a+ ?1 \New Faculty! K, G" j: h+ i+ R* g$ g. }$ k9 P
Phase 2 NCT00910650
4 t5 F! y, L* L) [
" F* i: e. e- v- s  n; _Katja Piltti0 ~  p% Y" q& r6 t. @$ A
Aileen Anderson
1 s' y: m% U" _% b- S" DStem Cells, Inc        Spinal cord injury
" }) C; z8 I2 @Training; n# |% m( f# m: p) ~( V: `
Phase 1/2% ]5 j2 E( D  T# W" N& x$ M
NCT013213337 I: p# o( ~/ x0 k, ~3 s4 l
! i2 i$ P( l3 P3 p  q; x6 c
Stephen Forman
/ S2 w7 V& Z: ?# Q5 y; M1 h9 rCity of Hope
! W( t9 U5 u+ q: E: r7 jGlioblastoma' j1 |, g& _. a) }2 D
Early Translation III
( ~; {( z' K7 |0 e0 ~Phase 1 NCT02208362+ l1 y; C8 _9 R8 A+ W. e

6 l5 l# u) q# t5 x2 xAntoni Ribas6 p/ h$ P8 J+ z& X) i
Jonsson Comprehensive Cancer Center: f) V1 v) ^4 l+ l
Advanced malignancies; i. g# v9 k: Y
New Faculty$ G! E; `( r! d% r( f8 f+ ^
Phase 2 NCT016975271 _& J% _4 k0 E+ c) c* k, @

+ K; o7 l/ y5 VPeter Coffey8 @( F' ]! T7 {) ~- k% o  W
Pfizer        Blindness7 r; A  D  |% V" Z* r
Leadership Award
& C9 m, n' U! l# [1 M1 [: w1 dPhase 1 NCT01691261
) F' c4 ~8 V' e, a# t) J2 |# R; [. ^. X, L/ n( {

/ h- c% e3 G* A